Engineering Microorganisms into Powerful Micromachines: Can Synthetic Biology Foster Bio-Revolution?
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Achieving global goals such as mass-scale food production and sustainable low-cost manufacturing methods is the need of the hour. Synthetic Biology (SynBio) is a field of science that has grown over the last two decades to emerge as a mature area in biological engineering with its potential to reduce the costs of biological production methods and improve the global food supply. It also can be crucial to create patient-centric drugs and promote precision medicine for better health outcomes.
SynBio is commercialized in two major stages: ‘biofoundry’ where new biotechnologies are rapidly designed, built, and tested, and ‘biorefinery’ where the newly formed products are scaled, demonstrated, and mass-produced. Total funding in SynBio has surpassed $4B by August 2021, primarily aimed at bioingredients development and life sciences research. Low-cost biomanufacturing and DNA sequencing methods have sparked investor interest in exploring SynBio into food manufacturing and therapeutics.
This report highlights the importance of SynBio in the design and creation of biological entities that do not exist in nature or reengineer existing biological systems to develop products like medicines, chemicals, ingredients, and advanced materials to revolutionize the way we live and build a sustainable economy.
What are the market dynamics in synthetic biology (SynBio)?
SynBio has the potential to reduce the costs of biological production methods and become a key solution to improve the global food supply. SynBio technologies can assist in biomanufacturing to potentially reduce industrial carbon emissions into the atmosphere. It integrates digitalization with intelligent biological principles to create biofertilizers and pesticides that cause no harm to human and aquatic life. SynBio can be crucial to create patient-centric drugs and promote personalized medicine. CAR-T-cells represent the most relevant SynBio-inspired therapeutics to target cancer treatments.
What are the brand-new applications of SynBio potential?
Space: Via its BioNutrients experiment, NASA is testing an in-space nutrient production method that uses genetically engineered baker’s yeast to produce specific antioxidants in space.
Automotive: Bio-rubber and other types of elastomers obtained by fusing SynBio can be used in the tire and soft part industries.
Mining: Biomining with the aid of SynBio could envisage the use of acidophilic microbes to facilitate the recovery process of metals from sulfide minerals in the processes of bioleaching and bio-oxidation. SynBio could be increasingly used in biomining processes.
Utilities: For bio-inspired electrocatalysts microorganisms can create biocatalysts, the direct coupling of which to electron transport can produce high-energy aviation fuels.
Packaging: Replacing traditional polymers such as polyvinyl chloride and polypropylene, PHA bioplastics obtained via SynBio route can be used in convenience food packaging.
Other potential areas: In artificial photosynthesis research, SynBio enables the optimization of existing photosynthetic systems to create new photosynthetic systems that do not exist in nature to generate new plant phenotypes.
Country-wise share by VC deals value, Jan 2016- June2021
For more country-level insights, download a free report sample
Who are the players in synthetic bio?
SynBio companies design and build biological systems that process information, create chemicals, fabricate materials and structures to enhance the quality of human health. Key players include Abbvie, Absci, ADM, Adrestia, AgBiome, Agilent, Agrigenetics, Agrimetis, Bruker, Calysta, Calyxt, Cargill, GRO Biosciences, and Hera BioLabs.
Market report scope
New application potential | Space, automotive, utilities, mining packaging and other areas |
Companies Covered | Abbvie, Absci, ADM, Adrestia, AgBiome, Agilent, Agrigenetics, Agrimetis, Bruker, Calysta, Calyxt, Cargill, GRO Biosciences, Hera BioLabs, Hexagon Bio, Hitachi, Hookipa Biotech, Hoxton Farms, Huawei, Human Genome Sciences, Humane Genomics, IBM, ICRISAT, igenebio, Illumina among others. |
Scope
- Technology Decoding: presents the technology overview, key features, market drivers, major applications, and a market map with potential use cases and popular companies.
- Media & Trend Analysis: highlights the technology presentation from the media perspective, mainly major news and social media mentions promoting the technology. The section also includes mentions of SynBio technologies from company annual and other filings as well as recent job trends and postings from big corporations.
- Investment Radar: outlines the venture capital funding trends with some of the popular deals, areas where the smart money is flowing, and notable investors and accelerators pumping money into the technology growth.
- Innovation Explorer: highlights the game-changing biotech company and startup innovations, as well as select strategic initiatives of enterprises inclined at new product development. The section also captures innovative biofoundaries and presents SynBio products which penetrated phase III trials and higher stages.
- IP Landscaping: provides a top-level analysis of the trends in patent filings and grants, priority countries, key patent filers by industry segmentation, and use cases.
- The Road Ahead: summarizes the drivers and challenges, use cases that can become successful with business leaders, potential applications in new horizons, and the outlook of the technology in near future.
Reasons to Buy
GlobalData’s FutureTech Series Reports are aimed at capturing futuristic technologies which have the potential to disrupt tomorrow. These technologies are constantly changing, adapting, and progressing to enable a paradigm shift in our daily lives. The awareness, knowledge, and expertise of these topics help transform business models and strategic thinking with an in-depth understanding of mega trends that can directly influence patenting, collaboration, acquisition, and investment decisions.
10X Genomics
23&me
4DMT
AB InBev
Abbvie
Absci
ADM
Adrestia
AgBiome
Agilent
Agrigenetics
Agrimetis
Agrivida
Air Protein
Alexandria Real Estate Equity Inc
Allonnia
Amgen
Amunix
Amyris
Andes
Antheia
Apeel Biosciences
AquaBounty Technologies
ARCH Venture Capital
Arkema
Arsenal Bio
Artios
Artiva
Arzeda
Asimov
AstraZeneca
Atlas Venture Inc
Atomwise
AzarGen Biotechnologies
Azitra
Bactolife
BASF
BASF Venture Capital
Bayer
Beam Therapeutics
Beijing Biocytogen
Benson Hill
BEOnChip
BGI
Biogen
Biomason
Bio-Rad
Biota
Bolt Therapeutics
Bolt Threads
Bota Biosciences
BP
Bristol Meyers
Bruker
Calysta
Calyxt
Cargill
Caribou Biosciences
Celgene
Cellarity
Cellectis
CG Oncology
China National Chemical Corp
Chromatin
CinderBio
Clara Foods
Clariant
Coca Cola
Codexis
Conagen
Corbion
Corteva
Cysbio
Danaher
Decode Genetics
Dell
Dow
DSM
Dupont
Editas Medicine
eGenesis
ElevateBio
Eligo Bioscience
EnginZyme
Evolva Holdings
Evolve Biosystems
Evonik
ExxonMobil
Flagship Pioneering
Future Fields
Future Meat
GE Research
Genecis
Genedata
Genome Company
Genomic Vision
Genopole
Gent Bio
Gingko Bioworks
GlycosBio
GreenLight Biosciences
GRO Biosciences
Hera BioLabs
Hexagon Bio
Hitachi
Hookipa Biotech
Hoxton Farms
Huawei
Human Genome Sciences
Humane Genomics
IBM
ICRISAT
igenebio
Illumina
Impossible Foods
Inari
Industrial Microbes
Ineos
Inscripta
Insitro
GlaxoSmithKline
Integrated DNA Technologies
JLabs
Johnson & Johnson
Just Foods
Kaiima
Keygene
Kheiron
Khosla Ventures
Kinnva
Kite Pharma
Kriya Therapeutics
L’Oreal
Lab Central
Lanzatech
Leaps by Bayer
Light Bio
Lonza
Lululemon
Lux Capital
Lygos
Mammoth Biosciences
Manus Bio
Meatable
Merck
Michelin
Microsoft
Modern Meadow
Monsanto
Mosa Meat
Motif
Mussel Polymers
Nature’s Sources
Nebula Genomics
New Age Meats
Nike
Nomad Foods
Novartis
Novartis Ventures
Novo Nordisk Foundation
Novoloop
Novozymes
NRGene
Omega Therapeutics
Orbimed Ventures
Origin Bio
Outpace
P&G
Pandion Therapeutics
Pepsico
Perfect Day
Perkin Elmer
Pfizer
Pfizer Ventures
Photanol
Pivot Bio
Plant Sensory Systems
Polaris Private Equity
Poseida Therapeutics
Precigen
Precision Biosciences
rBio
Recombinetics Inc.
Recursion
Redefine Meats
Regeneron Pharmaceuticals
Reliance Industries Limited
Resilience
Roche
S.V Health Ventures
SABIC
Saint-Gobain
Samsung
Sanatech Seeds
Sangamo
Sankyo Co Ltd
Sanofi
Scribe Therapeutics
Seattle Genetics
Second Genome
SentiBio
Shape Therapeutics
Shell
Shenyang Tonglian
Sherlock Biosciences
Sinopec
Siolta Therapeutics
Soffinova Ventures
Sonoma
Sony
Spiber
Startup Health
Stratcode
Sumitomo
Syngenta
Synlogic
Synthace
Synthego
Synthekine
Tata Chemicals
Terravia
TeselaGen
Thermo Fisher Scientific
Triton Algae Innovations
Twist Biosciences
Unilever
Upside Foods
Verily
Verve Therapeutics
Viridos
Zymergen
Visolis
Vivet Therapeutics
WarpBio
Werewolf Therapeutics
Y Combinator
Yara
Zydus Cadilla
ZymoChem
Table of Contents
Frequently asked questions
-
What are the companies covered in the SynBio?
Abbvie, Absci, ADM, Adrestia, AgBiome, Agilent, Agrigenetics, Agrimetis, Bruker, Calysta, Calyxt, Cargill, GRO Biosciences, Hera BioLabs are few of the companies covered.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.